Revelation Biosciences REVB
NASDAQ REVB
$3.62 -0.13 (-3.47%)
As of: Oct 21, 2026 · 3:59 PM EDT

Revelation Biosciences (REVB) Operating Leases (2025 - 2026)

Updated

Revelation Biosciences (REVB) recorded Operating Leases of $550,546 in Q2 2026, down 13.7% from the prior quarter.

Analysis

Revelation Biosciences (REVB) Operating Leases (2025 - 2026) Analysis & Trends

At the end of FY2025, Revelation Biosciences reported Operating Leases of $723,771.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Revelation Biosciences 13.82 Mn -35.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 550,546.00
Mar 31, 2026 638,183.00
Dec 31, 2025 723,771.00
API Access

Revelation Biosciences Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=REVB&period=max&api_key=YOUR_API_KEY